MX2021008176A - Inhibidores imidazo[1,2-b]piridazina de il-17a. - Google Patents

Inhibidores imidazo[1,2-b]piridazina de il-17a.

Info

Publication number
MX2021008176A
MX2021008176A MX2021008176A MX2021008176A MX2021008176A MX 2021008176 A MX2021008176 A MX 2021008176A MX 2021008176 A MX2021008176 A MX 2021008176A MX 2021008176 A MX2021008176 A MX 2021008176A MX 2021008176 A MX2021008176 A MX 2021008176A
Authority
MX
Mexico
Prior art keywords
inhibitors
imidazo
pyridazine
formula
imidazopyridazinyl
Prior art date
Application number
MX2021008176A
Other languages
English (en)
Inventor
David Andrew Coates
Spencer Brian Jones
Brian Morgan Watson
William Glen Holloway
Michael Enrico Richett
Kwame Frimpong
Adam Marc Levinson
Iii Charles Willis Lugar
Michael Edward Woodman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021008176A publication Critical patent/MX2021008176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona ciertos compuestos de difluorociclohexil-imidazopiridazinil-imidazolidinona de Fórmula II como inhibidores de IL-17A, composiciones farmacéuticas de estos, y métodos para usar un compuesto de la Fórmula II para tratar ciertos síntomas de psoriasis, artritis reumatoide o esclerosis múltiple. (ver Fórmula).
MX2021008176A 2019-01-07 2020-01-03 Inhibidores imidazo[1,2-b]piridazina de il-17a. MX2021008176A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789247P 2019-01-07 2019-01-07
US201962842770P 2019-05-03 2019-05-03
PCT/US2020/012115 WO2020146194A1 (en) 2019-01-07 2020-01-03 Imidazo[1,2-b]pyridazine il-17a inhibitors

Publications (1)

Publication Number Publication Date
MX2021008176A true MX2021008176A (es) 2021-10-13

Family

ID=69423406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008176A MX2021008176A (es) 2019-01-07 2020-01-03 Inhibidores imidazo[1,2-b]piridazina de il-17a.

Country Status (22)

Country Link
US (1) US20220073526A1 (es)
EP (1) EP3908585B1 (es)
JP (1) JP7291226B2 (es)
KR (1) KR102600451B1 (es)
CN (1) CN113286795B (es)
AU (1) AU2020207196B2 (es)
BR (1) BR112021011095B1 (es)
CA (1) CA3125788C (es)
CL (1) CL2021001720A1 (es)
CO (1) CO2021008776A2 (es)
CR (1) CR20210357A (es)
DO (1) DOP2021000132A (es)
EC (1) ECSP21050201A (es)
IL (1) IL284228B2 (es)
JO (1) JOP20210179A1 (es)
MA (1) MA54696A (es)
MX (1) MX2021008176A (es)
PE (1) PE20212304A1 (es)
SA (1) SA521422452B1 (es)
SG (1) SG11202105776WA (es)
TW (2) TW202214648A (es)
WO (1) WO2020146194A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127685A1 (en) 2018-12-19 2020-06-25 Leo Pharma A/S Amino-acid anilides as small molecule modulators of il-17
PE20230469A1 (es) 2020-04-30 2023-03-14 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17
KR20230024361A (ko) 2020-06-12 2023-02-20 레오 파마 에이/에스 Il-17의 소분자 조절제
WO2021255085A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
WO2021255086A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
US20230227435A1 (en) 2020-06-18 2023-07-20 Leo Pharma A/S Small molecule modulators of il-17
EP3943495A1 (en) 2020-07-24 2022-01-26 Leo Pharma A/S Small molecule modulators of il-17
CN113999234B (zh) * 2020-07-28 2023-03-07 成都先导药物开发股份有限公司 一种免疫调节剂
WO2022096411A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
CA3199816A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
EP4259631A1 (en) 2020-12-14 2023-10-18 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
AR126255A1 (es) 2021-07-01 2023-10-04 UCB Biopharma SRL Derivados de imidazotriazina como moduladores de il-17
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
AU2022349687A1 (en) * 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
CA3233625A1 (en) * 2021-09-27 2023-03-30 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2023078319A1 (zh) * 2021-11-04 2023-05-11 海思科医药集团股份有限公司 一种可抑制il-17a的杂环化合物及其用途
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
CN114736104B (zh) * 2022-04-20 2024-04-19 上海恩氟佳科技有限公司 一种二氟乙醛缩半乙醇的合成方法
WO2023225664A1 (en) * 2022-05-19 2023-11-23 Dice Alpha, Inc. Lactam substituted imidazopyridazine il-17a modulators and uses thereof
GB202210731D0 (en) 2022-07-22 2022-09-07 UCB Biopharma SRL Therapeutic agents
WO2024115662A1 (en) 2022-12-02 2024-06-06 Leo Pharma A/S Small molecule modulators of il-17
WO2024138286A1 (en) * 2022-12-26 2024-07-04 Usynova Pharmaceuticals, Ltd. Il-17a modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
US20100216798A1 (en) * 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
WO2007104696A1 (en) * 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antimalarial agents having polyaromatic structure
US20100216820A1 (en) * 2006-11-13 2010-08-26 White Stephen L Thienopyrimidiones for treatment of inflammatory disorders and cancers
ES2666353T3 (es) * 2012-09-06 2018-05-04 Bristol-Myers Squibb Company Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
CN105992768B (zh) * 2013-12-10 2018-04-20 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

Also Published As

Publication number Publication date
CA3125788C (en) 2023-10-31
IL284228B2 (en) 2024-05-01
CO2021008776A2 (es) 2021-07-30
EP3908585B1 (en) 2024-03-06
IL284228A (en) 2021-08-31
CA3125788A1 (en) 2020-07-16
KR20210100143A (ko) 2021-08-13
CN113286795A (zh) 2021-08-20
US20220073526A1 (en) 2022-03-10
KR102600451B1 (ko) 2023-11-10
WO2020146194A1 (en) 2020-07-16
BR112021011095B1 (pt) 2023-11-28
SA521422452B1 (ar) 2023-12-05
AU2020207196B2 (en) 2022-03-17
SG11202105776WA (en) 2021-06-29
ECSP21050201A (es) 2021-08-31
BR112021011095A2 (pt) 2021-08-31
JP2022516654A (ja) 2022-03-01
TW202214648A (zh) 2022-04-16
TW202039505A (zh) 2020-11-01
MA54696A (fr) 2022-04-13
DOP2021000132A (es) 2021-07-22
CR20210357A (es) 2021-09-01
JOP20210179A1 (ar) 2023-01-30
IL284228B1 (en) 2024-01-01
TWI752400B (zh) 2022-01-11
EP3908585A1 (en) 2021-11-17
JP7291226B2 (ja) 2023-06-14
PE20212304A1 (es) 2021-12-10
AU2020207196A1 (en) 2021-06-17
CN113286795B (zh) 2023-11-03
CL2021001720A1 (es) 2022-01-21

Similar Documents

Publication Publication Date Title
CR20210357A (es) Inhibidores de il-17a de imidazo[1,2-b]piridazina
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MX2019013922A (es) Inhibidores novedosos de map4k1.
MX2020005873A (es) Compuestos de 6-azaindol.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
MX2020006168A (es) Compuestos de 4-azaindol.
PH12017501570B1 (en) Bicyclic ketone sulfonamide compounds
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
ATE542818T1 (de) Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
HK1067120A1 (en) Glutaminyl based dpiv inhibitors
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2020006613A (es) Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
WO2007124181A3 (en) Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
MX2020000005A (es) Pirrolopirimidina que inhibe cinasa 1 reguladora de la se?al de apoptosis (ask1) y derivados de pirrolopiridina.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
EA202191464A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ИНГИБИТОРЫ IL-17A
AR002755A1 (es) Compuestos antimicrobianos ciclohexenilo y ciclohexilo 2-disubstituidos, procedimiento para su preparacion y composiciones farmaceuticas que loscontienen.
MX2023000198A (es) Inhibidores de atr y usos de estos.